Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01626378 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
A Phase 3 study, sponsored by TauRx Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
NCT01626378: Completed Phase 3 study, sponsored by TauRx Therapeutics.
NCT01626378 is a Phase 3 study that has completed, run by TauRx Therapeutics. The registered enrollment target is 220 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01626378, a Phase 3 study, has completed, sponsored by TauRx Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the safety and efficacy of TRx0237 in the treatment of patients with behavioral variant frontotemporal dementia (bvFTD).
Interventions
- DRUG Placebo
- DRUG TRx0237
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01626378
The ClinicalTrials.gov registry entry for NCT01626378 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TauRx Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01626378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01626378 about?
NCT01626378 is a clinical study titled "Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)". The purpose of this study is to demonstrate the safety and efficacy of TRx0237 in the treatment of patients with behavioral variant frontotemporal dementia (bvFTD).
What is the current status of trial NCT01626378?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2013-05. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01626378?
The interventions under investigation include: Placebo (DRUG), TRx0237 (DRUG).
Who is sponsoring clinical trial NCT01626378?
This trial is sponsored by TauRx Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.